Teva- Pharmaceutical Industries Return on Equity

Teva- Pharmaceutical Industries posts a ROE of 9.1%. That is below the Healthcare sector average of 20.86%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near 20.86% is typical. Teva- Pharmaceutical Industries's 9.1% is lower that level. That is roughly 56.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Teva- Pharmaceutical Industries's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 9.1%; use YoY and peer views to separate noise from signal.

Context for TEVA's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 20.86%), and (3) consistency with growth and profitability. This page covers the first two; Teva- Pharmaceutical Industries's other metric pages and overview cover the third.

Judging Teva- Pharmaceutical Industries against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 9.1% here, then scan peer and history charts to see if the gap is persistent.